The United States and United Kingdom have finalized a sweeping pharmaceuticals agreement that reshapes global pricing dynamics, value assessment standards, and market access pathways. With tariff-free exports, higher UK cost-effectiveness thresholds, new MFN protections, and accelerated patient access, the deal signals a major shift in how both nations approach innovation, affordability, and industrial competitiveness. Here's what the changes mean for manufacturers, payers, and the future of global drug policy.